<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845607</url>
  </required_header>
  <id_info>
    <org_study_id>PASCA trial</org_study_id>
    <nct_id>NCT04845607</nct_id>
  </id_info>
  <brief_title>Prophylactic Amiodarone for Shockable Cardiac Arrest</brief_title>
  <official_title>Prophylactic Amiodarone for Shockable Cardiac Arrest During Targeted Post Cardiac Arrest Care: Multi-center, Open Labelled Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Won Young Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the prophylactic amiodarone can prevent&#xD;
      re-arrest with ventricular shockable rhythm in patients who treated with targeted temperature&#xD;
      management after return of spontaneous circulation from cardiac arrest which had been&#xD;
      shockable rhythm during CPR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cardiac arrest are in high risk of re-arrest during post cardiac arrest care&#xD;
      due to vulnerable heart state electrically and hemodynamically. Especially if patients who&#xD;
      had experienced shockable rhythms such as ventricular fibrillation or pulseless ventricular&#xD;
      tachycardia during CPR, then they are at high risk of developing shockable re-arrest.&#xD;
&#xD;
      However until now there has not been any evidence of prophylactic anti arrhythmic drug effect&#xD;
      during post cardiac arrest care.&#xD;
&#xD;
      Amiodarone is class III anti arrhythmic drug which has been used for conversion of&#xD;
      ventricular arrhythmia during CPR.&#xD;
&#xD;
      In this study we want to determine whether the prophylactic amiodarone can prevent re-arrest&#xD;
      with ventricular shockable rhythm or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with re-arrest by shockable rhythm</measure>
    <time_frame>5 days from return of spontaneous circulation</time_frame>
    <description>No recurrence of ventricular fibrillation or pulseless ventricular tachycardia</description>
  </primary_outcome>
  <other_outcome>
    <measure>3 month survivor</measure>
    <time_frame>3 months after the time of hospital discharge</time_frame>
    <description>mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>3 months neurological outcome</measure>
    <time_frame>3 months after the time of hospital discharge</time_frame>
    <description>cerebral performance scales 3, 4 and 5</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">302</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Ventricular Arrythmia</condition>
  <arm_group>
    <arm_group_label>Prophylactic amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone Injection</intervention_name>
    <description>Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.</description>
    <arm_group_label>Prophylactic amiodarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non traumatic cardiac arrest patients who had VF or pVT during CPR in ER&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 yr&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  non cardiac caused arrest such as hanging&#xD;
&#xD;
          -  previous amiodarone continuous infusion before radomization&#xD;
&#xD;
          -  sustained ventricular arrhythmia recurrence after ROSC&#xD;
&#xD;
          -  extracorporeal membrane oxygenation&#xD;
&#xD;
          -  contra indication for amiodarone&#xD;
&#xD;
          -  disagree with this research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Young Kim, MD,PhD</last_name>
      <phone>+82-2-3010-3350</phone>
      <email>wonpia73@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Won Young Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

